SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
212.3 EUR
+3.1 (+1.48%)
Overall SRT3 gets a fundamental rating of 3 out of 10. We evaluated SRT3 against 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. While showing a medium growth rate, SRT3 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
Each year in the past 5 years SRT3 has been profitable.
Each year in the past 5 years SRT3 had a positive operating cash flow.
1.2 Ratios
The Return On Assets of SRT3 (1.04%) is worse than 89.47% of its industry peers.
The Return On Equity of SRT3 (3.92%) is worse than 89.47% of its industry peers.
SRT3 has a Return On Invested Capital of 3.80%. This is in the lower half of the industry: SRT3 underperforms 78.95% of its industry peers.
SRT3 had an Average Return On Invested Capital over the past 3 years of 8.34%. This is in line with the industry average of 7.28%.
The 3 year average ROIC (8.34%) for SRT3 is well above the current ROIC(3.80%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROIC | 3.8% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
The Profit Margin of SRT3 (3.00%) is worse than 84.21% of its industry peers.
SRT3's Profit Margin has declined in the last couple of years.
The Operating Margin of SRT3 (12.48%) is worse than 73.68% of its industry peers.
SRT3's Operating Margin has declined in the last couple of years.
SRT3 has a Gross Margin of 45.76%. This is in the better half of the industry: SRT3 outperforms 73.68% of its industry peers.
SRT3's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
The number of shares outstanding for SRT3 has been increased compared to 1 year ago.
SRT3 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRT3 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.18 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
SRT3's Altman-Z score of 2.18 is in line compared to the rest of the industry. SRT3 outperforms 42.11% of its industry peers.
SRT3 has a debt to FCF ratio of 8.09. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.09 years to pay back of all of its debts.
With a Debt to FCF ratio value of 8.09, SRT3 is not doing good in the industry: 68.42% of the companies in the same industry are doing better.
SRT3 has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SRT3 (1.54) is worse than 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Altman-Z | 2.18 |
ROIC/WACC0.51
WACC7.4%
2.3 Liquidity
SRT3 has a Current Ratio of 1.39. This is a normal value and indicates that SRT3 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.39, SRT3 is doing worse than 73.68% of the companies in the same industry.
A Quick Ratio of 0.88 indicates that SRT3 may have some problems paying its short term obligations.
With a Quick ratio value of 0.88, SRT3 is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.21% over the past year.
Measured over the past years, SRT3 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -11.87% on average per year.
Looking at the last year, SRT3 shows a small growth in Revenue. The Revenue has grown by 3.80% in the last year.
Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 13.10% on average per year.
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
3.2 Future
Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.16% on average per year.
Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.92% on average per year.
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 48.80, SRT3 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, SRT3 is valued expensively inside the industry as 89.47% of the companies are valued cheaper.
The average S&P500 Price/Earnings ratio is at 27.55. SRT3 is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 35.62, which means the current valuation is very expensive for SRT3.
Based on the Price/Forward Earnings ratio, SRT3 is valued more expensive than 84.21% of the companies in the same industry.
SRT3 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.8 | ||
| Fwd PE | 35.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 73.68% of the companies in the same industry.
63.16% of the companies in the same industry are more expensive than SRT3, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.63 | ||
| EV/EBITDA | 22.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SRT3's earnings are expected to grow with 22.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.1
PEG (5Y)N/A
EPS Next 2Y20.61%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
SRT3 has a yearly dividend return of 0.42%, which is pretty low.
Compared to an average industry Dividend Yield of 0.69, SRT3 has a dividend in line with its industry peers.
With a Dividend Yield of 0.42, SRT3 pays less dividend than the S&P500 average, which is at 2.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
48.70% of the earnings are spent on dividend by SRT3. This is a bit on the high side, but may be sustainable.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.7%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
FRA:SRT3 (10/15/2025, 5:36:15 PM)
212.3
+3.1 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.90B
Analysts80
Price Target314.94 (48.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.33%
Min EPS beat(2)-10.52%
Max EPS beat(2)-4.13%
EPS beat(4)0
Avg EPS beat(4)-10.28%
Min EPS beat(4)-22.4%
Max EPS beat(4)-4.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.97%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.87%
PT rev (3m)-12.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.25%
EPS NY rev (1m)0.59%
EPS NY rev (3m)0.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.15%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-1.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.8 | ||
| Fwd PE | 35.62 | ||
| P/S | 4.58 | ||
| P/FCF | 27.63 | ||
| P/OCF | 17.3 | ||
| P/B | 5.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.69 |
EPS(TTM)4.35
EY2.05%
EPS(NY)5.96
Fwd EY2.81%
FCF(TTM)7.68
FCFY3.62%
OCF(TTM)12.27
OCFY5.78%
SpS46.31
BVpS35.5
TBVpS-35.06
PEG (NY)2.1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROCE | 5.11% | ||
| ROIC | 3.8% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 13.6% | ||
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% | ||
| FCFM | 16.59% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 80.56% | ||
| Cap/Sales | 9.91% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 552.64% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.18 |
F-Score7
WACC7.4%
ROIC/WACC0.51
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
EPS Next Y23.27%
EPS Next 2Y20.61%
EPS Next 3Y22.38%
EPS Next 5Y19.16%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
Revenue Next Year5.14%
Revenue Next 2Y7.17%
Revenue Next 3Y8.54%
Revenue Next 5Y8.92%
EBIT growth 1Y1.03%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.49%
FCF growth 1Y187.94%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y14.51%
OCF growth 3Y4.07%
OCF growth 5Y20.79%